Therapy (HBV)

Human Monoclonal Antibody Patent Issuance Announced

Published in Hepatitis Weekly, December 18th, 2000

XTL Biopharmaceuticals Ltd. (XTL) (XTL), Rehovot, Israel, announced that it has been issued U.S. Patent No. 6,146,629, (the "629 patent") entitled "Human Monoclonal Antibody Against Hepatitis B Virus Surface Antigen (HBVsAg)."

The patent, XTL's first for a specific antibody, covers human monoclonal antibodies (MAbs) directed against the hepatitis B virus (HBV) surface antigen (HbsAg). In addition, the patent covers pharmaceutical compositions for the treatment of HBV infection containing the antibodies. These antibodies can be given either as monotherapy or in combination with additional antiviral agents.

Mirit Lotan, PhD, XTL, stated, "XTL's...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Hepatitis Weekly

Source: Hepatitis Weekly (2000-12-18)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry